Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, consider the potential implications of ongoing and planned clinical trials using PARP inhibitors in combination with other therapies to treat men with prostate cancer including:
Karim Fizazi, MD, PhD
Institut Gustave Roussey
Joaquin Mateo, MD, PhD
Vall d’Hebron University Hospital,
Commentary from Nelson F. Sanchez, MD, on caring for transgender individuals, from the healthcare disparities they face to how healthcare professionals can improve their care, from Clinical Care Options (CCO)
Podcast with Dr. Nelson F. Sanchez on caring for transgender individuals, from the healthcare disparities they face to how HCPs can improve their care, from Clinical Care Options (CCO)
Clinical Care Options (CCO): Dr Heather Cheng answers audience questions from a live symposium on current and expanding role of PARP inhibitors in prostate cancer care
Clinical Care Options (CCO): Expert analysis from Drs. Daniel Petrylak and Toni Choueiri on key data in genitourinary cancers from ASCO GU 2022